Open AccessEffect of Abciximab on Prothrombin Activation and Thrombin Generation in Acute Coronary Syndromes Without ST-Segment Elevation
Author(s) -
Piera Angelica Merlini,
Alessandra Repetto,
Alessandro Lombardi,
A Vetrano,
Raffaela Fetiveau,
Claudio Cavallini,
Diego Sappè,
Alessandro Salvioni,
R Canziani,
Stefano Savonitto,
Pier Mannuccio Mannucci,
Diego Ardissino
Publication year - 2002
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/hc0802.104456
Subject(s) - abciximab , medicine , thrombin , cardiology , antithrombotic , placebo , antithrombin , hirudin , anesthesia , acute coronary syndrome , anticoagulant , st elevation , heparin , myocardial infarction , platelet , percutaneous coronary intervention , pathology , alternative medicine
Abciximab is very effective in reducing major cardiac events in patients undergoing interventional procedures. Its antithrombotic effect is primarily attributable to the blocking of platelet glycoprotein IIb/IIIa receptors, but recent evidence suggests that it may have a direct antithrombin effect. No data are available concerning the effect of abciximab on the in vivo markers of prothrombin activation and thrombin generation in patients with acute coronary syndromes without ST elevation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom